Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis

Calcified Tissue International

Volumn 59, Issue 1, 1996, Pages 6-11

  Ellerington, M C ^a,b   Hillard, T C ^a,b   Whitcroft, S I J ^a,b   Marsh, M S ^a,b   Lees, B ^a   Banks, L M ^c   Whitehead, M I ^b   Stevenson, J C ^a,d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bone mineral density; Calcitonin; Intranasal administration; Postmenopausal osteoporosis

Indexed keywords

NOSE SPRAY; SALCATONIN;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPISTAXIS; FEMALE; FEMUR NECK; HIP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TASTE DISORDER;

ADMINISTRATION, INTRANASAL; BONE DENSITY; BONE RESORPTION; CALCITONIN; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; FEMALE; FEMUR; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINE;

EID: 0030018582     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900076     Document Type: Article

References (19)

1. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC (1976) Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet i:1038-1041
2. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund K, Transbøl IB (1980) Prevention of early postmenopausal bone loss: a controlled 2-year study in 315 normal females. Eur J Clin Invest 10:273-279
3. Hillard TC, Whitcroft SJ, Marsh MS, Ellerington MC, Lees B, Whitehead MI, Stevenson JC (1994) Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 4:341-348
4. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295-303
5. MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Lealy MJR (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet i:900-902
6. Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet ii:1481-1483
7. Overgaard K, Riis BJ, Christiansen C, Pdenphant J, Johansen JS (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-442
8. Banks LM, Stevenson JC (1986) Modified method of spinal computed tomography for trabecular bone mineral measurements. J Comput Assist Tomogr 10:463-467
9. Kleerekoper M, Parfitt AM, Elliss BI (1984) Measurement of vertebral fracture rate in osteoporosis. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL (eds) Osteoporosis. Proc Copenhagen Int Symp on Osteoporosis, vol 1. Stiftsbogtrykkeri, Aalborg, pp 103-109
10. Melton LJ III, Kan SH, Frye MA, Wahner HW, OFallon WM, Riggs BL (1989) Epidemiology of vertebral fractures in women. Am J Epidemiol 129:1000-1011
11. Kanis JA (1991) Pathophysiology and treatment of Paget's disease of bone. Martin Dunitz Ltd, London, p 298
12. Reginster JY, Deroisy R, Denis D, Lecart MP, Sarlet N, Franchimont P (1988) Is there any place for salmon calcitonin in prevention of postmenopausal bone loss? Gynaecol Endocrinol 2:195-204
13. Rizzato G, Schiraldi G, Tosi G, Locicero S, Montemurro L, Zanni D, Sisti S (1989) Administration of salmon calcitonin nasal spray for long-term treatment of corticosteroid-induced osteoporosis. A preliminary report. Curr Ther Res 45:761-766
14. Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 305:556-561
15. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Vas AAL, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Cano RP, Rapado A, Ribot C (1992) Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 305:1124-1128
16. Storm T, Thamsborg G, Steiniche T, Genant HK, Srensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
17. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567
18. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downes RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
19. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT (1984) Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet i:821-824